Page 2 - Hypera Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Takeda's latest sale brings its total divestment value up to about $12.9 billion. (Takeda) After inking a slate of geography-specific product selloffs last year, Takeda has turned back to Japan. Takeda locked up a deal to sell four Type 2 diabetes meds in Japan to local drugmaker Teijin Pharma for 133 billion Japanese yen ($1.2 billion), freeing up the company to focus on its core businesses in gastroenterology, rare diseases, plasma-derived therapies, oncology and neuroscience. The move is the latest in Takeda's selloff spree, linked to a divesture goal it set alongside its Shire merger. The...

Alongside the race for Covid-19 treatments and vaccines, the industry has maintained momentum 2020’s headlines have been dominated by coronavirus since the first reports of a mysterious virus causing pneumonia in Wuhan, China, in January. The pharmaceuticals sector’s response was huge. While the pharma landscape has been somewhat unusual this year, at least some business has carried on. The need for effective and innovative ways to treat disease is something that even a global pandemic will not blunt Of course, a lot of the focus on clinical trials this year has been Covid-19-related, but...